Radioactive drug trial seeks to target Hard-to-Treat tumors
NCT ID NCT07165132
Summary
This first-in-human study aims to test the safety and find the right dose of a new radioactive drug called RYZ401 for people with advanced neuroendocrine tumors and other solid tumors. The treatment delivers radiation directly to cancer cells that have specific markers. The study will enroll about 104 adults with tumors that show up on special imaging scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.